Metabolic Oncology 2.0
A Practical Framework for Targeting Cancer Through Fuel, Oxygen, and Metabolic Adaptation
IntroductionA new paradigm is emerging in oncology:Cancer can be influenced not only through pharmacological treatments, but also through its metabolic environment.
Traditionally, cancer metabolism has been described through two dominant fuels: glucose, via aerobic glycolysis (the Warburg effect), and glutamine, which supports biosynthesis and mitochondrial function. This framework has led to growing interest in metabolic interventions such as the Fasting Mimicking Diet (FMD) and Hyperbaric Oxygen Therapy (HBOT).
However, this model is incomplete.A growing body of research shows that many tumors can also utilize fatty acids, particularly under metabolic stress or therapeutic pressure. This shifts the paradigm from targeting one or two fuels to managing metabolic flexibility as a whole.
Part 1 — General Metabolic Considerations
Cancer is not a single metabolic disease.
Rather than relying on one pathway, cancer cells can use multiple fuels depending on environmental conditions:
Glucose supports rapid proliferation.
Glutamine supports biosynthesis and redox balance.
Fatty acids support survival, resistance, and adaptation through fatty acid oxidation.
The defining feature of cancer metabolism is not a single fuel dependency, but the ability to switch between fuels.
When glucose is restricted, tumor cells may increase reliance on glutamine or fatty acids. When lipid availability is high, fatty acid oxidation can become more prominent. When oxygen availability increases, mitochondrial metabolism may be enhanced.
This metabolic flexibility is a major driver of resistance.
Therefore, the objective of metabolic therapy is not simply to deprive cancer of fuel, but to limit its ability to adapt.
The Core Strategy: Cyclical Metabolic Stress
A systems-based approach to cancer metabolism relies on controlled metabolic cycling rather than constant restriction.A structured cycle includes:
A baseline phase with controlled fuel availability.
A stress phase that applies coordinated metabolic pressure.
A recovery phase that preserves physiological resilience.This cyclical approach reduces the likelihood of metabolic adaptation while maintaining patient safety.
The Three Core Tools
Fasting Mimicking Diet (FMD)
The FMD is a low-calorie, low-protein dietary intervention designed to mimic fasting while maintaining safety and compliance.It induces reduced blood glucose, reduced insulin and IGF-1 signaling, reduced mTOR activity, reduced amino acid signaling, and increased lipolysis and ketone production.The result is systemic metabolic reprogramming rather than simple caloric restriction.Importantly, the FMD induces differential stress resistance. Healthy cells activate protective and repair mechanisms, while cancer cells remain metabolically inflexible and vulnerable.
Hyperbaric Oxygen Therapy (HBOT)
HBOT increases oxygen delivery to tissues by elevating dissolved oxygen in plasma.Its biological effects include reduction of tumor hypoxia, increased mitochondrial activity, increased production of reactive oxygen species, and induction of oxidative stress in tumor cells.Reactive oxygen species are normal metabolic byproducts. Oxidative stress occurs when these molecules exceed the cell’s antioxidant capacity.Cancer cells often operate near this threshold, making them particularly sensitive to further increases in oxidative stress.
Exercise, IL-15 and EWOT
Exercise introduces a third important dimension: immune activation.Physical activity increases IL-15, a cytokine that plays a central role in activating natural killer cells and enhancing anti-tumor immunity. Exercise also improves circulation and supports immune surveillance.When combined with oxygen delivery, as in EWOT (Exercise With Oxygen Therapy), these effects may be enhanced through improved tissue oxygenation and systemic activation.In addition, EWOT can contribute to mild metabolic stress and improved physiological resilience.In the general setting, EWOT can be a useful complementary tool to support immune function, circulation, and overall metabolic health.
A Simple, Actionable Cycle (General Use)
A practical clinical rhythm can be structured as a 28-day cycle.
Days 1 to 16: baseline phase
Diet is low in glucose, moderate in protein, and controlled in fat.
Physical activity is light to moderate.
EWOT can be included two to three times per week at moderate intensity.
The goal is to support immune activation, circulation, and overall physiological function without excessive stress.
Days 17 to 21: stress phase
The FMD protocol is implemented.
HBOT is applied daily or near-daily.
Polyphenols and metabolic stressors such as berberine may be added.
EWOT is avoided during this phase to prevent excessive systemic stress and catabolism.
Days 22 to 28: recovery phase
Gradual refeeding.
Avoid extreme dietary shifts.
EWOT may be reintroduced lightly once or twice during this phase to support recovery and immune function.This cycle can be repeated for two to three iterations before reassessment.
Part 2 — FAO-Adaptive Tumors
A subset of tumors demonstrates a strong reliance on fatty acid oxidation.
These include prostate cancer, triple-negative breast cancer, ovarian cancer, acute myeloid leukemia, melanoma, and certain adaptive forms of glioblastoma.
In these cancers, fatty acids are not secondary fuels. They can play a central role in survival, metastasis, and resistance to therapy.
Tumor cells may increase fatty acid uptake, transport, and mitochondrial oxidation under metabolic stress. This allows them to compensate when glucose or glutamine availability is reduced.
This has important implications.
Protocols that rely heavily on prolonged ketogenic diets or high fat intake may unintentionally support tumor metabolism in these cases.
Updated Strategy for FAO-Adaptive Tumors
The objective shifts from restricting a single fuel to avoiding any dominant energy source.
This includes avoiding prolonged ketosis, maintaining low glucose availability, and controlling fat intake rather than increasing it.
The Fasting Mimicking Diet becomes the primary driver of metabolic stress, while Hyperbaric Oxygen Therapy remains an important tool to increase oxidative pressure.
Exercise and oxygen-based activation strategies such as EWOT must be used carefully in this context.
While EWOT can support immune function through mechanisms such as IL-15-mediated activation of natural killer cells, it also increases mitochondrial activity and fatty acid oxidation.
In tumors that are capable of using fatty acids efficiently, this may support survival pathways rather than suppress them.
For this reason, EWOT should be used sparingly or avoided in FAO-adaptive tumors, depending on the clinical context.
Simple, Actionable Plan for FAO Tumors
Days 1 to 16: baseline phase
Diet is low in glucose, moderate in protein, and controlled in fat.
No ketogenic diet is used.
Physical activity is kept light to moderate.
Days 17 to 21: stress phase
The FMD protocol is implemented.
HBOT is applied daily.
Polyphenols and metabolic stressors are added.
EWOT is avoided during this phase.
Recovery phase
Gradual refeeding with continued control of fat intake.
This cycle should be repeated for two cycles before reassessment.
Final Perspective
The central question is no longer: What fuel does cancer use?
The more relevant question is: What fuel will it switch to under stress?
Effective metabolic therapy does not rely on a single intervention, but on shaping a metabolic environment that limits adaptation, increases oxidative stress, and supports immune function.
The future of oncology may lie not only in stronger drugs, but in more intelligent control of metabolic conditions.
The most effective strategy is not the most aggressive one, but the one cancer cannot adapt to.
ReferencesLongo VD, Mattson MP. Cell Metabolism. 2014
Brandhorst S et al. Cell Metabolism. 2015
Seyfried TN. Cancer as a Metabolic Disease. 2012
Seyfried TN et al. Nutrition & Metabolism. 2020
Poff AM et al. PLoS One. 2013
Wallace DC. Nature Reviews Cancer. 2012
Nieman KM et al. Nature Medicine. 2011
Tabe Y et al. Frontiers in Oncology. 2020
Carracedo A et al. Nature Reviews Cancer. 2013
Kant S et al. Cancer Research. 2020
